Serrapeptase
Fifty years of regional drug use and a systematic review that still says insufficient.
D+
Evidence grade
D
Worth it
$12-22/month
Typical cost
DoseProducts provide 10 to 30 mg (marketed in 'SPU' activity units, typically 40,000 to 120,000 per day), taken on an empty stomach as an enteric-coated tablet, because the enzyme is a protein that digestion dismantles, the absorption problem this whole category shares and rarely mentions.
BasisSerrapeptase is an enzyme with a plausible anti-inflammatory mechanism, fifty years of anecdotal and regional-drug use, and a formal evidence review that says insufficient.
Serrapeptase (serratiopeptidase) is a proteolytic enzyme originally isolated from silkworm gut bacteria, sold for inflammation, swelling, sinus congestion, and pain. We grade Serrapeptase D+ on evidence and D for worth-it at about $12-22 per month.
What it does
Serrapeptase (serratiopeptidase) is a proteolytic enzyme originally isolated from silkworm gut bacteria, sold for inflammation, swelling, sinus congestion, and pain. It is half of this extension's systemic-enzyme pair, with lumbrokinase graded alongside it in this library.
What the research says
Scattered small trials suggest anti-edema and mucus effects; a systematic review found the file insufficient
Evidence: weak. Serratiopeptidase has decades of use as a drug in Japan and India and a trial literature to match its age rather than its market size: small studies on post-operative swelling, ankle sprains, carpal tunnel symptoms, and respiratory mucus, mostly short, mostly low quality, several decades old. A 2017 systematic review concluded the evidence is insufficient to support its use for any indication. Nothing since has changed that verdict materially.
Serrapeptase is an enzyme with a plausible anti-inflammatory mechanism, fifty years of anecdotal and regional-drug use, and a formal evidence review that says insufficient. Its bioavailability as an intact oral protein is itself doubtful. D+: the claim has had every opportunity to generate proof and has produced small old trials instead.
Is it worth it?
Evidence (D+) sits far below the leaderboard floor, so the worth-it grade is capped at C+; the derived value lands at D. About $17 a month at common doses. Derived from the October 2026 worth-it model.
Typical cost
$12-22/month
Common form, not a brand recommendation
Dosage context established
Products provide 10 to 30 mg (marketed in 'SPU' activity units, typically 40,000 to 120,000 per day), taken on an empty stomach as an enteric-coated tablet, because the enzyme is a protein that digestion dismantles, the absorption problem this whole category shares and rarely mentions.
Worth-it leaderboard
Serrapeptase sits outside the worth-it top 20.
Serrapeptase sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Generally tolerated; GI upset and rare skin reactions are reported. As a proteolytic enzyme with fibrinolytic claims, it belongs on the caution list around surgery and alongside anticoagulant or antiplatelet medication, by the same precautionary logic this library applies to nattokinase, and case reports of bleeding exist. Not for use in pregnancy on absent data.
Longevity Lab Report
Serrapeptase news. Graded when it happens.
The grade on this page stays free. The email carries the news on serrapeptase: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the systematic review and the underlying small-trial literature. Serrapeptase's long commercial life in two large drug markets is recorded here as what it is: regulatory history in systems that grandfathered it, not trial evidence.
- 2026-10-23|Not listed under any goal: no graded benefit exists to map.
The week's longevity and biohacking news.
This grade for Serrapeptase rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.